Global Information
회사소개 | 문의 | 비교리스트

위 억제성 폴리펩타이드 수용체(GIPR) : 파이프라인 리뷰

Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 358351
페이지 정보 영문 53 Pages
가격
US $ 3,500 ₩ 4,193,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,387,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,581,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


위 억제성 폴리펩타이드 수용체(GIPR) : 파이프라인 리뷰 Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 53 Pages

위 억제성 폴리펩타이드 수용체(GIPR : Gastric Inhibitory Polypeptide Receptor) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관에 의해서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

위 억제성 폴리펩타이드 수용체(GIPR) 개요

치료제 개발

  • 위 억제성 폴리펩타이드 수용체(GIPR) : 개발중인 제품 - 개발 단계별
  • 위 억제성 폴리펩타이드 수용체(GIPR) : 개발중인 제품 - 치료 범위별
  • 위 억제성 폴리펩타이드 수용체(GIPR) : 개발중인 제품 - 적응증별

위 억제성 폴리펩타이드 수용체(GIPR) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

위 억제성 폴리펩타이드 수용체(GIPR) : 기업에서 개발중인 제품

위 억제성 폴리펩타이드 수용체(GIPR) : 대학/기관에서 개발중인 제품

위 억제성 폴리펩타이드 수용체(GIPR) : 치료제 평가

  • 단독요법/병용요법 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

위 억제성 폴리펩타이드 수용체(GIPR) 치료제 개발에 참여하고 있는 기업

  • Alchemia Limited
  • AstraZeneca Plc
  • Carmot Therapeutics, Inc.
  • Diabetica Limited
  • Longevity Biotech, Inc
  • Novo Nordisk A/S
  • Sanofi
  • Zealand Pharma A/S

위 억제성 폴리펩타이드 수용체(GIPR) 치료제 개요

위 억제성 폴리펩타이드 수용체(GIPR) : 휴지중인 프로젝트

위 억제성 폴리펩타이드 수용체(GIPR) : 개발이 중지된 제품

위 억제성 폴리펩타이드 수용체(GIPR) : 주요 뉴스와 프레스 릴리스

부록

KSM 16.06.03

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Antag Therapeutics ApS, H1 2020
  • Pipeline by Bainan Biotech ApS, H1 2020
  • Pipeline by Carmot Therapeutics Inc, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
  • Pipeline by Kariya Pharmaceuticals IVS, H1 2020
  • Pipeline by Longevity Biotech Inc, H1 2020
  • Pipeline by Novo Nordisk AS, H1 2020
  • Pipeline by Zealand Pharma AS, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 4, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Gastrointestinal and Musculoskeletal Disorders which include indications Obesity, Type 2 Diabetes, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH), Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Circadian Rhythm Sleep Disorders, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Primary Sclerosing Cholangitis.

The latest report Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
  • The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
  • Antag Therapeutics ApS
  • Bainan Biotech ApS
  • Carmot Therapeutics Inc
  • Eli Lilly and Co
  • Hanmi Pharmaceuticals Co Ltd
  • Kariya Pharmaceuticals IVS
  • Longevity Biotech Inc
  • Novo Nordisk AS
  • Zealand Pharma AS
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
  • Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-868 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DAJC-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-15211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KP-405 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBT-6030 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NN-9423 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides to Antagonize GIPR for Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Agonize GIPR and GLP1R for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tirzepatide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
  • Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 11, 2020: Hanmi's NASH treatment wins more orphan drug status
  • Feb 28, 2020: Hanmi's anti-NASH drug candidate set to become 'game changer' in global pharmaceutical market
  • Jun 08, 2019: Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Associations 79 Scientific Sessions
  • May 29, 2019: Lilly announces webcast to discuss on tirzepatide at the American Diabetes Association's 79th Scientific Sessions
  • Dec 19, 2018: Carmot Therapeutics initiates phase 1 trial to treat type 2 diabetes
  • Oct 05, 2018: Lilly reports positive results for GIP/GLP-1 RA in type 2 diabetes trial
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q